Home » Topics » BioWorld Science

BioWorld Science
RSS

Adocia reports phase I data on BioChaperone Pramlintide Insulin in type 1 diabetes

Sep. 6, 2018

OncoArendi Therapeutics presents new AMCase and CHIT1 dual inhibitors for lung diseases

Sep. 6, 2018

Enanta Pharmaceuticals divulges new NR1H4 agonists

Sep. 6, 2018

Argenx initiates phase III trial of efgartigimod in generalized myasthenia gravis

Sep. 6, 2018

Daewoong Pharmaceutical patents EPRS inhibitors

Sep. 6, 2018

Summit Therapeutics names lead clinical candidate for gonorrhea

Sep. 6, 2018

Phase I/II interim data on QR-110 in LCA10 support progression to phase II/III

Sep. 6, 2018

CB-59 and CB-81, two small-molecule tau aggregation inhibitors with CNS drug-like properties

Sep. 6, 2018

Phase I/II results with pegzilarginase in arginase deficiency support upcoming pivotal trial

Sep. 6, 2018

GT-73 demonstrates efficacy in various in vivo models

Sep. 6, 2018

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...